6st2
Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs
Structural highlights
FunctionB2CL1_HUMAN Potent inhibitor of cell death. Inhibits activation of caspases (By similarity). Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.[1] [2] Isoform Bcl-X(S) promotes apoptosis.[3] [4] Publication Abstract from PubMedThe BCL-2 family is a challenging group of proteins to target selectively due to sequence and structural homologies across the family. Selective ligands for the BCL-2 family regulators of apoptosis are useful as probes to understand cell biology and apoptotic signalling pathways, and as starting points for inhibitor design. We have used phage display to isolate Affimer reagents (non-antibody binding proteins based on a conserved scaffold) to identify ligands for MCL-1, BCL-xL, BCL-2, BAK and BAX, then used multiple biophysical characterisation methods to probe the interactions. We established that purified Affimers elicit selective recognition of their target BCL-2 protein. For anti-apoptotic targets BCL-xL and MCL-1, competitive inhibition of their canonical protein-protein interactions is demonstrated. Co-crystal structures reveal an unprecedented mode of molecular recognition; where a BH3 helix is normally bound, flexible loops from the Affimer dock into the BH3 binding cleft. Moreover, the Affimers induce a change in the target proteins towards a desirable drug bound like conformation. These proof of concept studies indicate that Affimers could be used as alternative templates to inspire design of selective BCL-2 family modulators and more generally other protein-protein interaction inhibitors. Selective Affimers Recognize the BCL-2 Family Proteins BCL-xL and MCL-1 through Non-Canonical Structural Motifs.,Miles J, Hobor F, Trinh C, Taylor J, Tiede C, Rowell P, Jackson B, Nadat F, Ramsahye P, Kyle H, Wicky B, Clarke J, Tomlinson D, Wilson A, Edwards T Chembiochem. 2020 Sep 22. doi: 10.1002/cbic.202000585. PMID:32961017[5] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||||
